This article is more than 5 years old. Information may no longer be current.
Top 5 research updates from San Antonio Breast Cancer Symposium
Click Here to Manage Email Alerts
SAN ANTONIO — This year’s San Antonio Breast Cancer Symposium featured approximately 1,400 papers that provided new insights into breast cancer treatment, detection and prevention.
HemOnc Today presents five key studies from the meeting that could have considerable impact on patient care.
1. Pathologic complete response appeared to be a viable surrogate outcome for EFS and distant RFS, according to long-term efficacy results from the I-SPY2 trial. Read more.
2. Circulating tumor cells showed clinical validity as a prognostic biomarker for late recurrence of hormone receptor-positive, HER-2-negative early breast cancer. Read more.
3. Increasing the dose intensity of adjuvant chemotherapy reduced breast cancer recurrence and mortality, according to results of a large meta-analysis conducted by the Early Breast Cancer Clinical Trialists’ Collaborative Group. Read more.
4. Extending bisphosphonate treatment from 2 years to 5 years failed to prolong DFS or OS for patients with high-risk early-stage breast cancer, according to results of the phase 3 SUCCESS A trial. Read more.
5. Pembrolizumab plus trastuzumab appeared well tolerated and showed clinical benefit for women with advanced HER-2-positive breast cancer with PD-L1-positive tumors that were resistant to trastuzumab. Read more.